2026-11-05 コロンビア大学
米国コロンビア大学などの研究チームは、薬物注射を行い、HIV感染リスクとオピオイド使用障害を抱える人々を対象に、移動診療車を活用した統合医療サービスの有効性を無作為化比較試験HPTN 094で検証した。米国5都市の成人409人を対象に、移動診療車でHIV曝露前予防薬(PrEP)、オピオイド使用障害治療薬(MOUD)、医療・生活支援を提供するグループと、地域医療機関への紹介を中心とするグループを比較した。その結果、52週時点の死亡者数は介入群4人、比較群13人で、死亡ハザードは約71%低かった。一方、26週時点のPrEPおよびMOUD利用率には有意差が認められなかった。本研究は、医療機関へのアクセスが困難な人々に医療サービスを直接届ける移動型・統合型医療モデルが、死亡率の改善に寄与する可能性を示している。
<関連情報>
- https://sig.columbia.edu/news/bringing-care-closer-nih-funded-clinical-trial-integrated-health-services-through-mobile
- https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2855932
薬物注射使用者に対する依存症治療とHIV予防サービスの統合型移動診療:HPTN 094ランダム化臨床試験
Mobile Units for Integrated Addiction and HIV Prevention Services for People Who Inject Drugs: The HPTN 094 Randomized Clinical Trial
Steven Shoptaw, Nabila El-Bassel, Brett Hanscom, Timothy Skalland, Cecile Denis, David Goodman-Meza, Irene Kuo, Jordan E. Lake, Ellen A.B. Morrison, Amy M. Richards, Jessica M. Fogel, Paul Richardson, Mark A. Marzinke, William Clarke, Rahul PaulChoudhury, Jayla Harris-Wisecarver, Melissa Cummings, Redonna Chandler, Dale R. Burwen, Philip Andrew
JAMA Psychiatry, 2026; Published online November 4, 2026
DOI:10.1001/jamapsychiatry.2026.3644

People who inject drugs face substantial risks of HIV infection and opioid use disorder (OUD), while experiencing significant barriers to accessing healthcare and maintaining treatment. This study evaluated the effectiveness of mobile healthcare services integrating HIV preexposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD). A randomized clinical trial was conducted across five US cities involving 409 adults who currently injected drugs, were HIV-negative, and had OUD. Participants were assigned to either a 26-week intervention involving integrated healthcare delivered through mobile units and peer navigation (n = 203), or peer navigation to existing community-based healthcare services (n = 206). At 26 weeks, confirmed PrEP use was 5.4% in the mobile intervention group and 2.9% in the control group, while MOUD use was 14.8% and 10.7%, respectively. Neither primary outcome showed a statistically significant difference between groups. Similar results were observed at 52 weeks. However, by week 52, four deaths had occurred in the mobile intervention group compared with 13 in the control group. The intervention was associated with a significantly lower risk of all-cause mortality (hazard ratio, 0.29; 95% CI, 0.1–0.9; P = .03). These findings suggest that integrated mobile healthcare delivery may contribute to reducing mortality among people who inject drugs. However, mortality was a secondary outcome, and further research is required to confirm this potential benefit.

